ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
After a screening evaluation including baseline clinical laboratory testing, a physical and
neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE®
followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second
injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6
weeks of the injection 1.